3Z-20-005

3Z-20-005 is a preclinical-stage small molecule drug candidate being developed by 3Z Studio (also known as 3Z Pharmaceuticals) for the treatment of neurological indications. It functions as an imidazoline I1 receptor agonist. The compound was identified through a drug repurposing strategy utilizing a unique zebrafish-based behavioral screening platform designed to discover therapeutic candidates for central nervous system (CNS) disorders. While the specific target indication within the neurological space has not been publicly disclosed, the company's research focus includes conditions such as attention deficit hyperactivity disorder (ADHD) and insomnia. 3Z-20-005 has demonstrated proof-of-concept (POC) in zebrafish models.